EVE – Extracellular Vesicle Ecosystem for Theranostic Platforms
EVE ecosystem helps Finnish extracellular vesicle (EV) inventions in academic research organisations turn into new biomedical business and SME companies to take over application areas of EV biomedicines and technologies to expand the business globally.
Blood cell derived EVs form completely new business area that holds great potential as a new drug delivery vehicles for pharma companies. Further modified EVs combined with biomolecules can solve the obstacles hampering the targeted drug delivery to CNS and cancer.
In combination with disease biomarkers, EVs offer excellent theranostic unit as a tool for early diagnosis and treatment monitoring. Globally growing market of EV biomarkers needs the tools to be developed. Together with Finnish SME technologies the sensitivity of EV characterisation and disease diagnostic is improved. Creating an asset to enter global market.